Revumenib Revises the Treatment Landscape for -r Leukemia.
作者信息
Heikamp Emily B, Armstrong Scott A
机构信息
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.
出版信息
J Clin Oncol. 2025 Jan;43(1):85-88. doi: 10.1200/JCO-24-01265. Epub 2024 Nov 7.
Abstract
摘要
相似文献
1
Revumenib Revises the Treatment Landscape for -r Leukemia.瑞武利布改变了-r白血病的治疗格局。
J Clin Oncol. 2025 Jan;43(1):85-88. doi: 10.1200/JCO-24-01265. Epub 2024 Nov 7.
2
Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in -Rearranged Acute Lymphoblastic and Myeloid Leukemia.Menin 抑制和 DOT1L 抑制协同作用在 - 重排急性淋巴细胞白血病和髓系白血病中的不同反应。
Int J Mol Sci. 2024 May 30;25(11):6020. doi: 10.3390/ijms25116020.
3
Menin Inhibition With Revumenib for -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).使用瑞武尼布抑制Menin治疗重排的复发或难治性急性白血病（AUGMENT-101）。
J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9.
4
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.使用瑞武尼布抑制Menin治疗NPM1突变的复发或难治性急性髓系白血病：AUGMENT-101研究
Blood. 2025 May 7. doi: 10.1182/blood.2025028357.
5
Revumenib: a new era in acute leukemia treatment.瑞武利布：急性白血病治疗的新时代。
Trends Cancer. 2025 Feb;11(2):81-83. doi: 10.1016/j.trecan.2025.01.006. Epub 2025 Jan 24.
6
Revumenib: First Approval.瑞武单抗：首次获批。
Drugs. 2025 Apr;85(4):577-583. doi: 10.1007/s40265-025-02161-5.
7
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.强效、选择性的 menin-KMT2A 抑制剂 JNJ-75276617（bleximenib）在 KMT2A 和 NPM1 改变的白血病中的临床前疗效。
Blood. 2024 Sep 12;144(11):1206-1220. doi: 10.1182/blood.2023022480.
8
Targeting menin for precision therapy in high-risk acute myeloid leukemia.靶向Menin用于高危急性髓系白血病的精准治疗。
Leuk Res Rep. 2024 Dec 18;23:100495. doi: 10.1016/j.lrr.2024.100495. eCollection 2025.
9
Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions.靶向白血病中Menin-KMT2A相互作用：经验教训与未来方向
Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35332.
10
Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia.失活赋予急性髓系白血病对Menin抑制剂瑞武尼布的耐药性。
bioRxiv. 2025 Mar 27:2025.03.24.644993. doi: 10.1101/2025.03.24.644993.
引用本文的文献
1
Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias.Menin抑制剂：针对难治性急性白血病特定基因亚型的新型靶向疗法。
Cancers (Basel). 2025 Jan 4;17(1):142. doi: 10.3390/cancers17010142.
本文引用的文献
1
Menin Inhibition With Revumenib for -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).使用瑞武尼布抑制Menin治疗重排的复发或难治性急性白血病（AUGMENT-101）。
J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9.
2
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.BRG1/BRM 抑制剂靶向 AML 干细胞，并与 BET 或 menin 抑制剂联合发挥优异的临床前疗效。
Blood. 2024 May 16;143(20):2059-2072. doi: 10.1182/blood.2023022832.
3
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.美佐利单抗单独使用以及与 MENIN 抑制剂联合使用在 KMT2A-r 和 NPM1c AML 的临床前模型中均有效。
Blood. 2024 Apr 11;143(15):1513-1527. doi: 10.1182/blood.2023021105.
4
Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.具有 UBTF 串联重复的急性髓系白血病对 menin 抑制剂敏感。
Blood. 2024 Feb 15;143(7):619-630. doi: 10.1182/blood.2023021359.
5
The MLL-Menin Interaction is a Therapeutic Vulnerability in -rearranged AML.MLL与Menin的相互作用是MLL重排急性髓系白血病中的一个治疗弱点。
Hemasphere. 2023 Jul 27;7(8):e935. doi: 10.1097/HS9.0000000000000935. eCollection 2023 Aug.
6
The KMT2A recombinome of acute leukemias in 2023.2023 年急性白血病中的 KMT2A 重排组。
Leukemia. 2023 May;37(5):988-1005. doi: 10.1038/s41375-023-01877-1. Epub 2023 Apr 5.
7
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.Menin 抑制剂 revumenib 在伴有 KMT2A 重排或 NPM1 突变的白血病中的应用。
Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15.
8
MEN1 mutations mediate clinical resistance to menin inhibition.MEN1 突变介导了对 menin 抑制的临床耐药性。
Nature. 2023 Mar;615(7954):913-919. doi: 10.1038/s41586-023-05755-9. Epub 2023 Mar 15.
9
Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.NPM1 突变体直接调控急性髓系白血病中的癌基因转录。
Cancer Discov. 2023 Mar 1;13(3):746-765. doi: 10.1158/2159-8290.CD-22-0366.
10
MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor.MOZ 和 Menin-MLL 复合物是胃肠道间质瘤中染色质结合和转录输出的互补调节因子。
Cancer Discov. 2022 Jul 6;12(7):1804-1823. doi: 10.1158/2159-8290.CD-21-0646.
Zotero 插件